PriceTargets.com logo

Gilead Sciences - GILD Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $86.85
  • Forecasted Upside: -1.49%
  • Number of Analysts: 23
  • Breakdown:
  • 0 Sell Ratings
  • 10 Hold Ratings
  • 11 Buy Ratings
  • 2 Strong Buy Ratings
$88.16 As of 10/22/2024 01:00 AM ET
▲ +1.87 (2.17%)

This chart shows the closing price for GILD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Gilead Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GILD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GILD

Analyst Price Target is $86.85
▼ -1.49% Downside Potential
This price target is based on 23 analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $86.85, with a high forecast of $105.00 and a low forecast of $69.00. The average price target represents a -1.49% upside from the last price of $88.16.

This chart shows the closing price for GILD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 23 investment analysts is to moderate buy stock in Gilead Sciences. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 12 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 12 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 2 strong buy ratings
  • 11 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2024

Latest Recommendations

  • 2 strong buy ratings
  • 11 buy ratings
  • 10 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/21/2024Leerink PartnrsUpgradeHold ➝ Strong-Buy
10/21/2024Leerink PartnersUpgradeMarket Perform ➝ Outperform$74.00 ➝ $96.00
10/17/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$85.00 ➝ $94.00
10/17/2024Sanford C. BernsteinInitiated CoverageOutperform$105.00
10/9/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$95.00 ➝ $100.00
10/7/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$76.00 ➝ $84.00
10/7/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$78.00 ➝ $100.00
10/4/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$74.00 ➝ $75.00
9/16/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$70.00 ➝ $70.00
9/11/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$95.00 ➝ $95.00
9/9/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$70.00 ➝ $70.00
9/4/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$72.00 ➝ $74.00
8/15/2024Truist FinancialBoost TargetHold ➝ Hold$82.00 ➝ $83.00
8/15/2024Needham & Company LLCReiterated RatingHold
8/9/2024Evercore ISIUpgradeStrong-Buy
8/9/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$71.00 ➝ $72.00
8/9/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$70.00 ➝ $70.00
8/9/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$80.00 ➝ $85.00
7/22/2024Cantor FitzgeraldLower TargetNeutral ➝ Neutral$75.00 ➝ $70.00
7/8/2024Raymond JamesUpgradeMarket Perform ➝ Outperform$93.00
7/1/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$74.00 ➝ $74.00
6/20/2024Robert W. BairdReiterated RatingNeutral ➝ Neutral$80.00 ➝ $80.00
6/14/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$74.00 ➝ $74.00
5/1/2024Maxim GroupLower TargetBuy$90.00 ➝ $85.00
4/29/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$80.00 ➝ $76.00
4/26/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$80.00 ➝ $78.00
4/26/2024TD CowenLower TargetBuy ➝ Buy$90.00 ➝ $85.00
4/26/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$76.00 ➝ $74.00
4/26/2024Needham & Company LLCReiterated RatingHold
4/24/2024HSBCUpgradeReduce ➝ Hold$69.00
4/19/2024OppenheimerReiterated RatingOutperform ➝ Outperform$105.00
4/17/2024UBS GroupLower TargetNeutral ➝ Neutral$81.00 ➝ $75.00
3/4/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$84.00 ➝ $77.00
2/22/2024MizuhoLower TargetBuy ➝ Buy$101.00 ➝ $90.00
2/22/2024Truist FinancialDowngradeBuy ➝ Hold$91.00 ➝ $82.00
2/14/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$76.00 ➝ $75.00
2/12/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$85.00 ➝ $80.00
2/12/2024OppenheimerLower TargetOutperform ➝ Outperform$115.00 ➝ $105.00
2/7/2024Cantor FitzgeraldLower TargetNeutral ➝ Neutral$80.00 ➝ $78.00
2/7/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$78.00 ➝ $76.00
2/7/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$90.00 ➝ $84.00
1/23/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$82.00 ➝ $85.00
11/14/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$78.00 ➝ $77.00
11/9/2023Deutsche Bank AktiengesellschaftInitiated CoverageHold$75.00
11/8/2023UBS GroupLower TargetNeutral ➝ Neutral$85.00 ➝ $84.00
10/11/2023Leerink PartnrsReiterated RatingMarket Perform
9/8/2023Bank of AmericaUpgradeNeutral ➝ Buy$88.00 ➝ $95.00
9/6/2023Truist FinancialReiterated RatingBuy ➝ Buy$91.00
9/6/2023HSBCInitiated CoverageReduce$71.00
8/4/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$86.00 ➝ $88.00
8/4/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$83.00 ➝ $84.00
7/24/2023Piper SandlerLower TargetOverweight$105.00 ➝ $100.00
7/24/2023BarclaysLower TargetEqual Weight$81.00 ➝ $80.00
7/19/2023Cantor FitzgeraldLower TargetNeutral ➝ Neutral$85.00 ➝ $80.00
7/18/2023BMO Capital MarketsLower Target$100.00 ➝ $95.00
7/11/2023BarclaysLower Target$84.00 ➝ $81.00
5/16/2023BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$90.00 ➝ $100.00
4/12/2023Morgan StanleyBoost TargetEqual Weight$81.00 ➝ $85.00
3/6/2023Royal Bank of CanadaLower TargetSector Perform$87.00 ➝ $86.00
2/14/2023MizuhoBoost TargetBuy$88.00 ➝ $101.00
2/10/2023CowenBoost Target$90.00 ➝ $95.00
2/3/2023Leerink PartnersBoost TargetMarket Perform$81.00 ➝ $91.00
2/3/2023Morgan StanleyBoost TargetEqual Weight$80.00 ➝ $81.00
2/3/2023Robert W. BairdBoost Target$69.00 ➝ $80.00
2/3/2023Piper SandlerBoost TargetOverweight$111.00 ➝ $112.00
1/24/2023Morgan StanleyLower TargetEqual Weight$81.00 ➝ $80.00
1/19/2023Piper SandlerBoost TargetOverweight$104.00 ➝ $111.00
1/18/2023BarclaysBoost TargetEqual Weight$76.00 ➝ $84.00
1/3/2023Wells Fargo & CompanyBoost TargetEqual Weight$75.00 ➝ $90.00
1/3/2023Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$87.00
12/21/2022MizuhoInitiated CoverageBuy$88.00
12/13/2022Bank of AmericaReiterated RatingNeutral$85.00
12/9/2022DZ BankDowngradeBuy ➝ Hold$90.00
12/1/2022Morgan StanleyBoost TargetEqual Weight$68.00 ➝ $81.00
12/1/2022OppenheimerBoost Target$95.00 ➝ $105.00
11/9/2022ArgusBoost Target$70.00 ➝ $100.00
11/8/2022CowenBoost TargetOutperform$80.00 ➝ $90.00
11/8/2022CowenBoost TargetOutperform$80.00 ➝ $90.00
11/8/2022MizuhoBoost TargetBuy$75.00 ➝ $88.00
11/1/2022Robert W. BairdBoost Target$69.00
11/1/2022Leerink PartnersBoost TargetMarket Perform$68.00 ➝ $81.00
10/31/2022Maxim GroupBoost TargetBuy$84.00 ➝ $92.00
10/31/2022BarclaysUpgradeUnderweight ➝ Equal Weight$60.00 ➝ $76.00
10/28/2022Morgan StanleyBoost TargetEqual Weight$67.00 ➝ $68.00
10/28/2022Royal Bank of CanadaBoost TargetOutperform$79.00 ➝ $82.00
10/28/2022JPMorgan Chase & Co.Boost TargetOverweight$80.00 ➝ $87.00
10/28/2022Jefferies Financial GroupBoost TargetBuy$78.00 ➝ $86.00
10/28/2022Wells Fargo & CompanyBoost TargetEqual Weight$74.00 ➝ $75.00
10/28/2022CowenBoost TargetOutperform$75.00 ➝ $80.00
10/28/2022BMO Capital MarketsBoost TargetMarket Perform$63.00 ➝ $72.00
10/28/2022CowenBoost Target$75.00 ➝ $80.00
10/28/2022Piper SandlerUpgradeNeutral ➝ Overweight$79.00 ➝ $96.00
10/28/2022Truist FinancialUpgradeHold ➝ Buy$76.00 ➝ $91.00
10/13/2022Morgan StanleyBoost TargetEqual Weight$65.00 ➝ $67.00
10/12/2022BarclaysBoost TargetUnderweight$56.00 ➝ $60.00
10/4/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$72.00 ➝ $80.00
9/15/2022Leerink PartnersReiterated RatingMarket Perform
9/15/2022Truist FinancialBoost TargetHold$71.00 ➝ $76.00
9/13/2022Wells Fargo & CompanyBoost TargetEqual Weight$63.00 ➝ $74.00
9/12/2022Piper SandlerBoost Target$74.00 ➝ $79.00
8/15/2022Piper SandlerBoost Target$71.00 ➝ $74.00
7/15/2022Morgan StanleyBoost TargetEqual Weight$63.00 ➝ $65.00
7/12/2022Cantor FitzgeraldInitiated CoverageNeutral$70.00
6/7/2022BMO Capital MarketsInitiated CoverageHold$63.00
5/23/2022Leerink PartnersInitiated CoverageMarket Perform$68.00
5/16/2022Piper SandlerLower TargetNeutral$73.00 ➝ $69.00
4/29/2022Piper SandlerBoost Target$72.00 ➝ $73.00
4/12/2022Morgan StanleyLower TargetEqual Weight$69.00 ➝ $63.00
4/12/2022Royal Bank of CanadaBoost TargetOutperform$76.00 ➝ $77.00
4/12/2022Piper SandlerBoost Target$71.00 ➝ $72.00
4/4/2022Piper SandlerLower TargetNeutral$77.00 ➝ $71.00
3/22/2022Wells Fargo & CompanyLower TargetEqual Weight$70.00 ➝ $63.00
3/10/2022BarclaysLower TargetUnderweight$63.00 ➝ $56.00
3/8/2022BMO Capital MarketsInitiated CoverageHold$65.00
3/7/2022Royal Bank of CanadaLower TargetOutperform$85.00 ➝ $77.00
2/28/2022BMO Capital MarketsDowngradeOutperform ➝ Market Perform$75.00 ➝ $65.00
2/8/2022MizuhoLower TargetBuy$81.00 ➝ $75.00
2/3/2022Maxim GroupLower Target$88.00 ➝ $84.00
2/3/2022OppenheimerLower Target$100.00 ➝ $90.00
2/2/2022Morgan StanleyLower TargetEqual Weight$72.00 ➝ $69.00
2/2/2022Truist FinancialLower TargetHold$77.00 ➝ $75.00
2/2/2022Bank of AmericaLower TargetNeutral$73.00 ➝ $71.00
2/2/2022BMO Capital MarketsLower TargetOutperform$85.00 ➝ $75.00
2/2/2022Royal Bank of CanadaLower TargetOutperform$87.00 ➝ $85.00
2/2/2022Wells Fargo & CompanyLower TargetEqual Weight$72.00 ➝ $70.00
1/28/2022ArgusUpgradeHold ➝ Buy$75.00
1/18/2022Morgan StanleyLower TargetEqual Weight$74.00 ➝ $72.00
1/14/2022BMO Capital MarketsInitiated CoverageBuy$85.00
1/6/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$84.00 ➝ $74.00
12/15/2021BMO Capital MarketsReiterated RatingBuy
12/14/2021Leerink PartnersReiterated RatingBuy
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$72.00
12/6/2021The Goldman Sachs GroupInitiated CoverageNeutral$80.00
11/19/2021Piper SandlerInitiated CoverageNeutral$77.00
11/18/2021BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$72.00 ➝ $85.00
10/31/2021Evercore ISIReiterated RatingBuy
10/29/2021Leerink PartnersLower TargetOutperform$77.00 ➝ $75.00
10/12/2021Morgan StanleyBoost TargetOverweight$83.00 ➝ $84.00
8/27/2021Morgan StanleyReiterated RatingBuy$83.00
8/23/2021Royal Bank of CanadaReiterated RatingBuyC$84.00
7/30/2021Leerink PartnersBoost TargetOutperform$74.00 ➝ $77.00
7/30/2021BMO Capital MarketsBoost TargetMarket Perform$67.00 ➝ $72.00
7/30/2021Royal Bank of CanadaBoost TargetOutperform$81.00 ➝ $84.00
6/28/2021OppenheimerInitiated CoverageBuy$100.00
5/7/2021Jefferies Financial GroupReiterated RatingBuy$80.00
5/3/2021Morgan StanleyBoost TargetOverweight$81.00 ➝ $83.00
4/30/2021Leerink PartnersBoost TargetOutperform$72.00 ➝ $74.00
4/30/2021Needham & Company LLCReiterated RatingHold
4/19/2021Morgan StanleyLower TargetOverweight$87.00 ➝ $81.00
4/1/2021Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$80.00
3/30/2021Redburn PartnersUpgradeNeutral ➝ Buy
2/11/2021Leerink PartnersLower TargetOutperform$73.00 ➝ $72.00
2/5/2021Leerink PartnersLower TargetOutperform$74.00 ➝ $73.00
2/5/2021Credit Suisse GroupBoost TargetNeutral$65.00 ➝ $66.00
2/5/2021Morgan StanleyBoost TargetOverweight$83.00 ➝ $87.00
1/19/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight$83.00
1/4/2021GuggenheimUpgradeNeutral ➝ Buy
12/22/2020Smith Barney CitigroupLower Target$75.00 ➝ $72.00
12/18/2020Truist FinancialLower Target$67.00 ➝ $625.00
12/17/2020OppenheimerLower TargetOutperform$105.00 ➝ $100.00
12/16/2020BMO Capital MarketsLower TargetMarket Perform$64.00 ➝ $62.00
12/16/2020Credit Suisse GroupLower TargetNeutral$70.00 ➝ $65.00
12/16/2020Robert W. BairdBoost TargetNeutral$63.00 ➝ $67.00
12/15/2020Piper SandlerLower TargetOverweight$84.00 ➝ $80.00
12/14/2020Redburn PartnersInitiated CoverageNeutral
12/8/2020JPMorgan Chase & Co.Reiterated RatingHold
11/3/2020Morgan StanleyReiterated RatingEqual Weight$67.00
10/29/2020Cantor FitzgeraldReiterated RatingOverweight$84.00 ➝ $86.00
10/29/2020BMO Capital MarketsLower TargetMarket Perform$74.00 ➝ $64.00
10/29/2020BarclaysLower Target$67.00 ➝ $62.00
10/29/2020Wells Fargo & CompanyLower TargetEqual Weight$69.00 ➝ $63.00
10/29/2020Piper SandlerLower TargetOverweight$95.00 ➝ $84.00
10/29/2020Leerink PartnersLower TargetOutperform$88.00 ➝ $79.00
10/28/2020UBS GroupInitiated CoverageNeutral$61.00
9/30/2020Jefferies Financial GroupInitiated CoverageBuy$78.00
9/18/2020Royal Bank of CanadaBoost Target$82.00 ➝ $86.00
9/15/2020Royal Bank of CanadaLower TargetOutperform$84.00 ➝ $82.00
9/15/2020Maxim GroupUpgradeHold ➝ Buy$88.00
9/14/2020Leerink PartnersLower TargetOutperform$94.00 ➝ $88.00
9/14/2020Raymond JamesReiterated RatingHold
9/10/2020OppenheimerBoost TargetOutperform$90.00 ➝ $105.00
8/20/2020Truist FinancialLower Target$74.00 ➝ $67.00
8/19/2020Piper SandlerLower TargetOverweight$85.00 ➝ $83.00
8/19/2020Jefferies Financial GroupLower Target$97.00 ➝ $78.00
8/19/2020Wells Fargo & CompanyBoost TargetEqual Weight$69.00 ➝ $76.00
8/19/2020BMO Capital MarketsBoost TargetMarket Perform$74.00 ➝ $79.00
8/19/2020Cantor FitzgeraldLower TargetOverweight$86.00 ➝ $84.00
8/7/2020JPMorgan Chase & Co.Reiterated RatingHold
8/3/2020CitigroupBoost Target$78.00 ➝ $80.00
7/31/2020Leerink PartnersReiterated RatingBuy$95.00
7/31/2020Cantor FitzgeraldReiterated RatingBuy$86.00
7/31/2020Piper SandlerLower TargetOverweight$90.00 ➝ $85.00
7/31/2020Credit Suisse GroupLower TargetNeutral$75.00 ➝ $73.00
7/31/2020SunTrust BanksBoost TargetHold$73.00 ➝ $74.00
7/31/2020Royal Bank of CanadaLower TargetOutperform$89.00 ➝ $87.00
7/31/2020Morgan StanleyLower TargetEqual Weight$80.00 ➝ $79.00
7/31/2020Wells Fargo & CompanyLower TargetEqual Weight$87.00 ➝ $76.00
7/28/2020JPMorgan Chase & Co.Reiterated RatingHold$85.00
7/21/2020Jefferies Financial GroupReiterated RatingBuy$97.00
7/20/2020Credit Suisse GroupUpgradeUnderperform ➝ Neutral$64.00 ➝ $75.00
7/15/2020Morgan StanleyBoost TargetEqual Weight$77.00 ➝ $80.00
7/6/2020Royal Bank of CanadaReiterated RatingBuy
6/30/2020Needham & Company LLCReiterated RatingHold
6/29/2020Robert W. BairdReiterated RatingHold$76.00
6/22/2020Jefferies Financial GroupReiterated RatingBuy$97.00
6/15/2020DZ BankReiterated RatingBuy
6/8/2020Piper SandlerReiterated RatingBuy$90.00
6/3/2020Royal Bank of CanadaReiterated RatingBuy$88.00
6/3/2020Leerink PartnersUpgradeMarket Perform ➝ Outperform$85.00 ➝ $94.00
6/2/2020Maxim GroupReiterated RatingHold
6/1/2020Needham & Company LLCReiterated RatingHold
5/26/2020SunTrust BanksUpgradeSell ➝ Hold$70.00 ➝ $73.00
5/21/2020Piper SandlerReiterated RatingBuy$90.00
5/21/2020Robert W. BairdReiterated RatingHold$75.00
5/18/2020OppenheimerReiterated RatingBuy
5/13/2020MizuhoReiterated RatingBuy$81.00
5/13/2020JPMorgan Chase & Co.Reiterated RatingHold$85.00
5/5/2020Royal Bank of CanadaReiterated RatingBuy$88.00
5/1/2020Wells Fargo & CompanyReiterated RatingHold$84.00
5/1/2020Leerink PartnersBoost TargetMarket Perform$68.00 ➝ $85.00
5/1/2020OppenheimerBoost TargetOutperform$80.00 ➝ $90.00
5/1/2020Morgan StanleyBoost TargetEqual Weight$75.00 ➝ $77.00
5/1/2020Raymond JamesDowngradeOutperform ➝ Market Perform
5/1/2020SunTrust BanksDowngradeHold ➝ Sell$70.00
5/1/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
4/30/2020Maxim GroupReiterated RatingHold
4/29/2020OppenheimerInitiated CoverageBuy$80.00
4/29/2020Robert W. BairdReiterated RatingHold$76.00
4/29/2020CfraBoost TargetSell$71.00 ➝ $74.00
4/29/2020MizuhoReiterated RatingBuy$81.00
4/27/2020UBS GroupDowngradeBuy ➝ Neutral$77.00 ➝ $80.00
4/23/2020Royal Bank of CanadaReiterated RatingBuy$85.00
4/23/2020MizuhoInitiated CoverageBuy$81.00
4/23/2020Raymond JamesReiterated RatingBuy$80.00
4/20/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$79.00
4/20/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$87.00
4/19/2020Needham & Company LLCReiterated RatingHold
4/18/2020Maxim GroupInitiated CoverageHold
4/17/2020Credit Suisse GroupReiterated RatingSell$60.00
4/17/2020Royal Bank of CanadaReiterated RatingBuy$85.00
4/17/2020JPMorgan Chase & Co.Reiterated RatingBuy
4/17/2020CfraDowngradeHold ➝ Sell
4/16/2020Piper SandlerReiterated RatingBuy$90.00
4/13/2020Jefferies Financial GroupReiterated RatingBuy$89.00
4/13/2020CowenReiterated RatingBuy$80.00
4/13/2020BMO Capital MarketsReiterated RatingOutperform ➝ Buy$79.00
4/13/2020Needham & Company LLCReiterated RatingHold
4/7/2020Cantor FitzgeraldBoost TargetOverweight$78.00 ➝ $86.00
4/6/2020Credit Suisse GroupReiterated RatingSell$60.00
3/31/2020Wolfe ResearchInitiated CoverageMarket Perform$65.00
3/30/2020Leerink PartnersReiterated RatingHold$68.00
3/25/2020Royal Bank of CanadaReiterated RatingBuy$83.00
3/25/2020SunTrust BanksReiterated RatingHold
3/20/2020Piper SandlerUpgradeNeutral ➝ Overweight$70.00 ➝ $90.00
3/18/2020Royal Bank of CanadaReiterated RatingBuy$83.00
3/18/2020DZ BankUpgradeHold ➝ Buy$80.00
3/9/2020Royal Bank of CanadaDowngradeTop Pick ➝ Outperform$86.00
3/4/2020Wells Fargo & CompanyBoost TargetOverweight$81.00 ➝ $87.00
3/3/2020Credit Suisse GroupReiterated RatingUnderperform
3/2/2020MizuhoInitiated CoverageBuy$81.00
3/2/2020HC WainwrightDowngradeBuy ➝ Neutral
2/28/2020DZ BankDowngradeBuy ➝ Hold$80.00
2/27/2020BarclaysInitiated CoverageUnderweight$62.00
2/24/2020SunTrust BanksReiterated RatingHold$70.00
2/19/2020Royal Bank of CanadaReiterated RatingBuy$86.00
2/9/2020Maxim GroupReiterated RatingHold
2/6/2020Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$78.00 ➝ $70.00
2/5/2020Piper SandlerLower Target$75.00 ➝ $70.00
2/5/2020Bank of AmericaBoost TargetNeutral$70.00 ➝ $72.00
2/5/2020Credit Suisse GroupBoost TargetUnderperform$59.00 ➝ $60.00
2/5/2020JPMorgan Chase & Co.Reiterated RatingBuy
2/5/2020Raymond JamesDowngradeStrong-Buy ➝ Outperform$81.00 ➝ $80.00
1/21/2020GuggenheimDowngradeBuy ➝ Neutral
1/3/2020OppenheimerUpgradeMarket Perform ➝ Outperform
1/2/2020CowenReiterated RatingBuy$85.00
12/13/2019Credit Suisse GroupDowngradeNeutral ➝ Underperform$67.00 ➝ $63.00
11/12/2019SunTrust BanksInitiated CoverageHold$70.00
10/25/2019GuggenheimSet TargetBuy$86.00
10/25/2019Wells Fargo & CompanySet TargetBuy$81.00
10/25/2019Robert W. BairdSet TargetHold$76.00
10/25/2019Morgan StanleySet TargetHold$75.00
10/25/2019OppenheimerLower TargetOutperform$85.00 ➝ $80.00
10/25/2019Maxim GroupDowngradeBuy ➝ Hold
10/25/2019Cantor FitzgeraldLower TargetOverweight$88.00 ➝ $85.00
(Data available from 10/23/2019 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 25 very positive mentions
  • 47 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 44 very positive mentions
  • 21 positive mentions
  • 10 negative mentions
  • 2 very negative mentions
Mentions as of
4/26/2024
  • 37 very positive mentions
  • 28 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/26/2024
  • 53 very positive mentions
  • 27 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
6/25/2024
  • 38 very positive mentions
  • 21 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
7/25/2024
  • 44 very positive mentions
  • 33 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
8/24/2024
  • 40 very positive mentions
  • 31 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2024
  • 41 very positive mentions
  • 33 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
10/23/2024

Current Sentiment

  • 41 very positive mentions
  • 33 positive mentions
  • 4 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Gilead Sciences logo
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $88.16
Low: $85.61
High: $88.36

50 Day Range

MA: $81.61
Low: $73.78
High: $88.16

52 Week Range

Now: $88.16
Low: $62.07
High: $88.36

Volume

6,029,354 shs

Average Volume

7,062,263 shs

Market Capitalization

$109.83 billion

P/E Ratio

107.51

Dividend Yield

3.53%

Beta

0.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Gilead Sciences?

The following equities research analysts have issued stock ratings on Gilead Sciences in the last year: Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, Evercore ISI, HSBC Holdings plc, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Maxim Group, Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, StockNews.com, TD Cowen, Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for GILD.

What is the current price target for Gilead Sciences?

20 Wall Street analysts have set twelve-month price targets for Gilead Sciences in the last year. Their average twelve-month price target is $86.85, suggesting a possible downside of 1.5%. Oppenheimer Holdings Inc. has the highest price target set, predicting GILD will reach $105.00 in the next twelve months. HSBC Holdings plc has the lowest price target set, forecasting a price of $69.00 for Gilead Sciences in the next year.
View the latest price targets for GILD.

What is the current consensus analyst rating for Gilead Sciences?

Gilead Sciences currently has 10 hold ratings, 11 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for GILD.

What other companies compete with Gilead Sciences?

Other companies that are similar to Gilead Sciences include Amgen, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Seagen and Alnylam Pharmaceuticals. Learn More about companies similar to Gilead Sciences.

How do I contact Gilead Sciences' investor relations team?

Gilead Sciences' physical mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company's listed phone number is (650) 574-3000 and its investor relations email address is [email protected]. The official website for Gilead Sciences is www.gilead.com. Learn More about contacing Gilead Sciences investor relations.